

Albert J Czaja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4800950/publications.pdf>

Version: 2024-02-01

290
papers

26,031
citations

4641

85
h-index

7333

152
g-index

300
all docs

300
docs citations

300
times ranked

7532
citing authors

#	ARTICLE	IF	CITATIONS
1	International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 31, 929-938.	1.8	2,681
2	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	3.6	1,553
3	Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , 2010, 51, 2193-2213.	3.6	1,243
4	Diagnosis and treatment of autoimmune hepatitis. <i>Hepatology</i> , 2002, 36, 479-497.	3.6	509
5	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
6	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	2.6	451
7	Frequency and nature of the variant syndromes of autoimmune liver disease. <i>Hepatology</i> , 1998, 28, 360-365.	3.6	328
8	Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. <i>Gastroenterology</i> , 1993, 105, 1824-1832.	0.6	297
9	Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1996, 110, 848-857.	0.6	287
10	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18017.	18.1	280
11	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 2515.	1.4	272
12	Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1997, 112, 2028-2035.	0.6	257
13	Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. <i>Hepatology</i> , 1997, 25, 317-323.	3.6	255
14	Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 58-72.e4.	0.6	252
15	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , 2000, 31, 49-53.	3.6	233
16	Drug-Induced Autoimmune-Like Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 958-976.	1.1	229
17	Host- and disease-specific factors affecting steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 1998, 29, 198-206.	1.8	227
18	Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Journal of Hepatology</i> , 2004, 40, 646-652.	1.8	220

#	ARTICLE	IF	CITATIONS
19	Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. <i>Gastroenterology</i> , 1992, 103, 1290-1295.	0.6	205
20	Significance of HLA DR4 in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1993, 105, 1502-1507.	0.6	198
21	The Variant Forms of Autoimmune Hepatitis. <i>Annals of Internal Medicine</i> , 1996, 125, 588.	2.0	196
22	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1996, 24, 1068-1073.	3.6	190
23	Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. <i>Immunological Reviews</i> , 2000, 174, 250-259.	2.8	188
24	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Hepatology</i> , 1992, 15, 215-221.	3.6	187
25	Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. <i>Hepatology</i> , 2006, 43, 532-538.	3.6	186
26	Recurrent autoimmune hepatitis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 302-310.	1.3	185
27	High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. <i>Gastroenterology</i> , 1995, 108, 1159-1166.	0.6	181
28	Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 1540-1548.	3.6	179
29	Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1999, 30, 851-856.	3.6	178
30	Autoimmune hepatitis with incidental histologic features of bile duct injury. <i>Hepatology</i> , 2001, 34, 659-665.	3.6	174
31	Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 30, 394-401.	1.8	173
32	Complete Resolution of Inflammatory Activity Following Corticosteroid Treatment of HBsAg-Negative Chronic Active Hepatitis. <i>Hepatology</i> , 1984, 4, 622-627.	3.6	164
33	Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1999, 117, 645-652.	0.6	163
34	The nature and prognostic implications of autoimmune hepatitis with an acute presentation. <i>Journal of Hepatology</i> , 1994, 21, 866-871.	1.8	159
35	Sequential histologic evaluations in collagenous colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1903-1909.	1.1	158
36	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2190-2195.	1.1	158

#	ARTICLE	IF	CITATIONS
37	Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. <i>Gut</i> , 2002, 51, 259-264.	6.1	158
38	Natural History, Clinical Features, and Treatment of Autoimmune Hepatitis. <i>Seminars in Liver Disease</i> , 1984, 4, 1-12.	1.8	157
39	Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. <i>Journal of Hepatology</i> , 1992, 14, 325-331.	1.8	157
40	Improving the End Point of Corticosteroid Therapy in Type 1 Autoimmune Hepatitis to Reduce the Frequency of Relapse. <i>American Journal of Gastroenterology</i> , 2007, 102, 1005-1012.	0.2	156
41	Autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 435-456.	1.1	154
42	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , 1983, 85, 713-717.	0.6	151
43	Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. <i>Gastroenterology</i> , 1993, 105, 1522-1528.	0.6	150
44	Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. <i>Hepatology</i> , 2002, 35, 890-897.	3.6	148
45	Autoantibodies in liver disease. <i>Gastroenterology</i> , 2001, 120, 239-249.	0.6	144
46	The validity and importance of subtypes in autoimmune hepatitis: a point of view. <i>American Journal of Gastroenterology</i> , 1995, 90, 1206-11.	0.2	142
47	Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. <i>Hepatology</i> , 2007, 46, 1138-1145.	3.6	139
48	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 413-419.	0.2	137
49	Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser) ^{Sec} complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. <i>Clinical and Experimental Immunology</i> , 2000, 121, 364-374.	1.1	135
50	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , 1981, 80, 687-692.	0.6	133
51	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. <i>Hepatology</i> , 1999, 30, 1381-1386.	3.6	133
52	Corticosteroid-Treated Chronic Active Hepatitis in Remission. <i>New England Journal of Medicine</i> , 1981, 304, 5-9.	13.9	130
53	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , 1980, 78, 518-523.	0.6	128
54	Immunologic features and HLA associations in chronic viral hepatitis. <i>Gastroenterology</i> , 1995, 108, 157-164.	0.6	128

#	ARTICLE	IF	CITATIONS
55	Validation of scoring system for diagnosis of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 305-314.	1.1	128
56	Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , 1988, 95, 448-453.	0.6	125
57	The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. <i>Hepatology</i> , 1989, 9, 193-197.	3.6	124
58	Autoimmune cholangitis within the spectrum of autoimmune liver disease. <i>Hepatology</i> , 2000, 31, 1231-1238.	3.6	124
59	Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. <i>Gastroenterology</i> , 2000, 119, 1312-1316.	0.6	124
60	Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 2051-2057.	0.2	124
61	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. <i>Gut and Liver</i> , 2016, 10, 177.	1.4	124
62	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
63	Genetic predispositions for the immunological features of chronic active hepatitis. <i>Hepatology</i> , 1993, 18, 816-822.	3.6	122
64	Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. <i>Gastroenterology</i> , 1994, 107, 200-207.	0.6	120
65	Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Hepatology</i> , 2004, 39, 1631-1638.	3.6	116
66	Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. <i>Journal of Hepatology</i> , 1993, 18, 342-352.	1.8	114
67	Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. <i>Journal of Hepatology</i> , 2002, 37, 302-308.	1.8	114
68	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. <i>Liver</i> , 1984, 4, 105-116.	0.1	113
69	Acute and Acute Severe (Fulminant) Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 897-914.	1.1	110
70	Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. <i>Digestive Diseases and Sciences</i> , 1986, 31, 705-711.	1.1	109
71	Understanding The Pathogenesis of Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1224-1231.	0.2	109
72	The nature and prognosis of severe cryptogenic chronic active hepatitis. <i>Gastroenterology</i> , 1993, 104, 1755-1761.	0.6	108

#	ARTICLE	IF	CITATIONS
73	Biopsy Findings and Clinical Correlations. <i>American Journal of Surgical Pathology</i> , 1995, 19, 699-708.	2.1	108
74	Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. <i>Journal of Hepatology</i> , 1996, 24, 52-59.	1.8	106
75	Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , 2009, 51, 161-167.	1.8	106
76	Consequences of treatment withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , 2007, 27, 507-515.	1.9	104
77	Treatment of Autoimmune Hepatitis. <i>Seminars in Liver Disease</i> , 2002, 22, 365-378.	1.8	101
78	The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. <i>Clinics in Liver Disease</i> , 2002, 6, 685-705.	1.0	97
79	Safety issues in the management of autoimmune hepatitis. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 319-333.	1.0	97
80	Genetic Factors Affecting the Occurrence, Clinical Phenotype, and Outcome of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 379-388.	2.4	93
81	Histological findings in chronic hepatitis C with autoimmune features. <i>Hepatology</i> , 1997, 26, 459-466.	3.6	90
82	Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1987, 92, 215-219.	0.6	89
83	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , 1997, 26, 567-572.	3.6	89
84	Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. <i>Liver Transplantation</i> , 2002, 8, 505-513.	1.3	89
85	Treatment challenges and investigational opportunities in autoimmune hepatitis. <i>Hepatology</i> , 2005, 41, 207-215.	3.6	89
86	Autoimmune hepatitis and its variant syndromes. <i>Gut</i> , 2001, 49, 589-594.	6.1	87
87	Hepatocellular carcinoma in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1944-1948.	1.1	86
88	Empiric Therapy of Autoimmune Hepatitis With Mycophenolate Mofetil. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 819-825.	1.1	86
89	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1984, 87, 1222-1227.	0.6	85
90	Genetic bases of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2139-2150.	1.1	85

#	ARTICLE	IF	CITATIONS
91	Predictive Factors for Hepatocellular Carcinoma in Type 1 Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1944-1951.	0.2	85
92	Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2248-2266.	1.1	84
93	Severe chronic active liver disease. <i>The American Journal of Digestive Diseases</i> , 1977, 22, 973-980.	0.9	83
94	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , 2007, 69, 227-235.	1.0	82
95	Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , 2003, 23, 116-123.	1.9	81
96	Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Hepatology</i> , 1988, 8, 1679-1683.	3.6	80
97	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. <i>Liver International</i> , 2004, 24, 322-329.	1.9	80
98	'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. <i>Clinical and Experimental Immunology</i> , 2004, 135, 154-158.	1.1	79
99	Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1688-1696.	1.1	78
100	Autoimmune hepatitis. Part A: pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 113-128.	1.4	77
101	Autoantibody-Negative Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 610-624.	1.1	75
102	Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Hepatology</i> , 1989, 10, 39-43.	3.6	74
103	Autoimmune hepatitis: The investigational and clinical challenges. <i>Hepatology</i> , 2000, 31, 1194-1200.	3.6	74
104	Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , 1990, 11, 1044-1049.	3.6	73
105	Thiopurine Methyltransferase Deficiency and Azathioprine Intolerance in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 968-975.	1.1	73
106	Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation. <i>Liver Transplantation</i> , 2007, 13, 953-955.	1.3	73
107	Autoantibodies as Prognostic Markers in Autoimmune Liver Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2144-2161.	1.1	72
108	Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 545-554.	1.1	70

#	ARTICLE	IF	CITATIONS
109	Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. <i>Liver International</i> , 2012, 32, 85-92.	1.9	70
110	Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 385-406.	1.9	69
111	Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 261-279.	1.9	68
112	Features and consequences of untreated type 1 autoimmune hepatitis. <i>Liver International</i> , 2009, 29, 816-823.	1.9	67
113	Drug Therapy in the Management of Type 1 Autoimmune Hepatitis. <i>Drugs</i> , 1999, 57, 49-68.	4.9	66
114	Difficult treatment decisions in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2010, 16, 934.	1.4	66
115	Chronic Active Hepatitis: The Challenge for a New Nomenclature. <i>Annals of Internal Medicine</i> , 1993, 119, 510.	2.0	63
116	Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1733-1740.	1.1	63
117	Immune phenotype of chronic liver disease. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2149-2155.	1.1	63
118	The Overlap Syndromes of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 58, 326-43.	1.1	62
119	Genetic distinctions between types 1 and 2 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 1997, 92, 2197-200.	0.2	62
120	Diagnosis and Management of the Overlap Syndromes of Autoimmune Hepatitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 417-423.	1.8	60
121	Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 691-707.	1.9	59
122	Recurrent and De Novo Autoimmune Hepatitis. <i>Liver Transplantation</i> , 2019, 25, 152-166.	1.3	59
123	Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , 1990, 98, 1587-1593.	0.6	58
124	Clinical Features and Prognostic Implications of Severe Corticosteroid-Treated Cryptogenic Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1990, 65, 23-30.	1.4	57
125	Frequency and significance of antibodies to histones in autoimmune hepatitis. <i>Journal of Hepatology</i> , 1995, 23, 32-38.	1.8	57
126	Treatment strategies in autoimmune hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, 799-824.	1.0	57

#	ARTICLE	IF	CITATIONS
127	Autoantibodies in the Diagnosis and Management of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 315-329.	1.1	56
128	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , 2005, 4, 6-24.	0.6	56
129	Frequency, Behavior, and Prognostic Implications of Antimitochondrial Antibodies in Type 1 Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 1047-1053.	1.1	56
130	Autoimmune hepatitis in diverse ethnic populations and geographical regions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 365-385.	1.4	56
131	Nonstandard Antibodies as Prognostic Markers in Autoimmune Hepatitis. <i>Autoimmunity</i> , 2004, 37, 195-201.	1.2	55
132	Cholestatic Phenotypes of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1430-1438.	2.4	55
133	Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9257.	1.4	55
134	Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2277-2292.	1.1	55
135	Current and future treatments of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 269-291.	1.4	53
136	Frequency and Significance of Antibodies to Soluble Liver Antigen/Liver Pancreas in Variant Autoimmune Hepatitis. <i>Autoimmunity</i> , 2002, 35, 475-483.	1.2	52
137	Shared genetic risk factors in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , 2001, 46, 140-147.	1.1	51
138	Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2881-2900.	1.1	51
139	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 859.	1.4	51
140	Optimizing Diagnosis From the Medical Liver Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 898-907.	2.4	50
141	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 343-364.	1.9	50
142	Autoantibodies in Autoimmune Liver Disease. <i>Advances in Clinical Chemistry</i> , 2005, 40, 127-164.	1.8	48
143	Special Clinical Challenges in Autoimmune Hepatitis: The Elderly, Males, Pregnancy, Mild Disease, Fulminant Onset, and Nonwhite Patients. <i>Seminars in Liver Disease</i> , 2009, 29, 315-330.	1.8	47
144	Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1459-1476.	1.1	47

#	ARTICLE	IF	CITATIONS
145	DIAGNOSIS AND THERAPY OF AUTOIMMUNE LIVER DISEASE. <i>Medical Clinics of North America</i> , 1996, 80, 973-994.	1.1	46
146	Cryptogenic Chronic Hepatitis and Its Changing Guise in Adults. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3421-3438.	1.1	46
147	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 173-182.	1.9	46
148	Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1028-1035.	1.1	44
149	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2007, 23, 255-262.	1.0	44
150	Current therapy for autoimmune hepatitis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 202-214.	1.7	44
151	Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the Elderly. <i>Drugs and Aging</i> , 2008, 25, 219-239.	1.3	44
152	Diagnosis and Management of Autoimmune Hepatitis. <i>Clinics in Liver Disease</i> , 2015, 19, 57-79.	1.0	44
153	Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, 707-725.	1.0	43
154	Comparability of Probable and Definite Autoimmune Hepatitis by International Diagnostic Scoring Criteria. <i>Gastroenterology</i> , 2011, 140, 1472-1480.	0.6	43
155	Advances in the Current Treatment of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1996-2010.	1.1	43
156	Targeting Apoptosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2890-2904.	1.1	42
157	Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A foray across diagnostic boundaries. <i>Journal of Hepatology</i> , 2006, 44, 251-252.	1.8	41
158	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , 1979, 77, 629-633.	0.6	39
159	Variant forms of autoimmune hepatitis. <i>Current Gastroenterology Reports</i> , 1999, 1, 63-70.	1.1	39
160	Current Concepts in the Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1237-1252.	1.4	39
161	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 33-40.	1.1	38
162	Frequency and significance of antibodies to chromatin in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1658-1664.	1.1	38

#	ARTICLE	IF	CITATIONS
163	Drug choices in autoimmune hepatitis: Part B – nonsteroids. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 617-635.	1.4	38
164	Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 324-344.	1.1	38
165	Extrahepatic Immunologic Features of Chronic Viral Hepatitis. <i>Digestive Diseases</i> , 1997, 15, 125-144.	0.8	37
166	Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 483-489.	1.4	36
167	Autoimmune Hepatitis: Focusing on Treatments other than Steroids. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 615-620.	1.8	36
168	Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. <i>World Journal of Gastroenterology</i> , 2009, 15, 2314.	1.4	36
169	Frequency and Significance of Antibody to Hepatitis C Virus in Severe Corticosteroid-Treated Autoimmune Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1991, 66, 572-582.	1.4	35
170	Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. <i>Liver International</i> , 2006, 26, 552-558.	1.9	35
171	Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis. <i>Current Pharmaceutical Design</i> , 2011, 17, 3120-3140.	0.9	35
172	Current and prospective pharmacotherapy for autoimmune hepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1715-1736.	0.9	35
173	Cell Mediators of Autoimmune Hepatitis and Their Therapeutic Implications. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1528-1542.	1.1	34
174	Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: A retrospective analysis. <i>Gastroenterology</i> , 1989, 97, 1288-1293.	0.6	33
175	Autoimmune chronic active hepatitis: A specific entity? The negative argument*. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 343-351.	1.4	33
176	Late Relapse of Type 1 Autoimmune Hepatitis After Corticosteroid Withdrawal. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1761-1769.	1.1	33
177	Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1322-1331.	1.1	32
178	Clinical significance of HLA DRB1*03:DRB1*04 in type 1 autoimmune hepatitis. <i>Liver International</i> , 2006, 26, 1201-1208.	1.9	32
179	Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1043-1058.	1.9	32
180	Review article: iron disturbances in chronic liver diseases other than haemochromatosis – pathogenic, prognostic, and therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 681-701.	1.9	32

#	ARTICLE	IF	CITATIONS
181	Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. <i>Mayo Clinic Proceedings</i> , 1980, 55, 360-4.	1.4	32
182	Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2098-2106.	1.1	31
183	Recurrence of nonalcoholic steatohepatitis after liver transplantation. <i>Liver Transplantation</i> , 1997, 3, 185-186.	1.9	31
184	Autoimmune hepatitis in special patient populations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 689-700.	1.0	31
185	Diverse manifestations and evolving treatments of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2005, 51, 313-33.	2.2	31
186	Autoimmune hepatitis. Part B: diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 129-143.	1.4	30
187	Drug choices in autoimmune hepatitis: Part A "steroids. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 603-615.	1.4	30
188	Epigenetic changes and their implications in autoimmune hepatitis. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12899.	1.7	30
189	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , 2020, 72, 753-769.	3.6	30
190	Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , 1982, 57, 303-9.	1.4	30
191	Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis. <i>Hepatology</i> , 1986, 6, 976-980.	3.6	29
192	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , 1983, 85, 713-7.	0.6	29
193	Frequency and Significance of Antibody to Hepatitis C Virus in Severe Corticosteroid-Treated Cryptogenic Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1990, 65, 1303-1313.	1.4	28
194	Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. <i>Journal of Hepatology</i> , 1992, 14, 88-93.	1.8	28
195	The immunoreactive propensity of autoimmune hepatitis: Is it corticosteroid-dependent after liver transplantation?. <i>Liver Transplantation</i> , 1999, 5, 460-463.	1.9	28
196	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3118-3139.	1.1	28
197	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , 1981, 80, 687-92.	0.6	28
198	Celiac Disease-Associated Autoimmune Cholangitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 3196-3198.	0.2	26

#	ARTICLE	IF	CITATIONS
199	Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2007, 52, 179-184.	1.1	26
200	Recurrent autoimmune hepatitis after liver transplantation: A disease continuum or a fresh start?. <i>Liver Transplantation</i> , 2009, 15, 1169-1171.	1.3	26
201	Emerging Opportunities for Site-Specific Molecular and Cellular Interventions in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2712-2726.	1.1	26
202	Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. <i>Journal of Hepatology</i> , 1993, 17, 180-186.	1.8	25
203	Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2784-2803.	1.1	25
204	Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1725-1731.	1.1	23
205	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. <i>World Journal of Gastroenterology</i> , 2019, 25, 6579-6606.	1.4	23
206	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , 1980, 78, 518-23.	0.6	23
207	Animal models of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 429-443.	1.4	22
208	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 345-364.	1.0	22
209	HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients. <i>Digestive Diseases and Sciences</i> , 2008, 53, 522-528.	1.1	21
210	Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 920-937.	1.9	21
211	How lupoid is lupoid hepatitis?. <i>Journal of Rheumatology</i> , 1986, 13, 95-8.	1.0	21
212	5 Autoantibodies. <i>Bailliere's Clinical Gastroenterology</i> , 1995, 9, 723-744.	0.9	20
213	Frequency and Significance of Antibodies to <i>Saccharomyces cerevisiae</i> in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2004, 49, 611-618.	1.1	20
214	Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. <i>Autoimmunity</i> , 2006, 39, 341-348.	1.2	20
215	Anti-tRNP(ser) ^{sec} /SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. <i>Liver International</i> , 2005, 25, 410-419.	1.9	19
216	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 215-222.	1.0	19

#	ARTICLE	IF	CITATIONS
217	Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. <i>Gastroenterology</i> , 1992, 102, 1675-1679.	0.6	18
218	Viral Genotypes as Determinants of Autoimmune Expression in Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 1999, 74, 454-460.	1.4	18
219	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 547-564.	1.4	18
220	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1996, 24, 1068-1073.	3.6	18
221	Current problems in the diagnosis and management of chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , 1981, 56, 311-23.	1.4	18
222	Frequency and significance of serum Î±-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1987, 93, 687-692.	0.6	17
223	Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree. <i>Journal of Hepatology</i> , 2009, 51, 8-10.	1.8	17
224	Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II. Inflammation and Allergy: Drug Targets, 2012, 11, 351-363.	1.8	17
225	Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I. Inflammation and Allergy: Drug Targets, 2012, 11, 337-350.	1.8	17
226	Challenges in the Diagnosis and Management of Autoimmune Hepatitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 531-539.	1.8	17
227	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1984, 87, 1222-7.	0.6	16
228	The role of autoantibodies as diagnostic markers of autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 33-48.	1.3	15
229	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 298-305.	1.0	15
230	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , 2005, 4, 6-24.	0.6	15
231	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 234-240.	1.0	14
232	Autoimmune liver disease and rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , 2007, 19, 74-80.	2.0	14
233	Systemic mycosis complicating high dose corticosteroid treatment of chronic active liver disease. <i>American Journal of Gastroenterology</i> , 1980, 74, 428-32.	0.2	14
234	Adoptive cell transfer in autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 821-836.	1.4	13

#	ARTICLE	IF	CITATIONS
235	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1706-1725.	1.1	13
236	Autoimmune hepatitis and viral infection. <i>Gastroenterology Clinics of North America</i> , 1994, 23, 547-66.	1.0	13
237	Emerging Treatments for Autoimmune Hepatitis. <i>Inflammation and Allergy: Drug Targets</i> , 2002, 1, 317-326.	3.1	12
238	Evolving paradigm of treatment for autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 781-798.	1.3	12
239	Malignancy in Chronic Liver Disease. <i>Gastroenterology</i> , 1977, 73, 192-193.	0.6	11
240	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 232-242.	1.0	11
241	Autoimmune hepatitis—approach to diagnosis. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 55.	0.2	11
242	Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2007, 53, 43-78.	2.2	11
243	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 231-240.	1.0	10
244	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 293-299.	1.0	10
245	Overlap syndromes. <i>Clinical Liver Disease</i> , 2014, 3, 2-5.	1.0	10
246	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10
247	Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2493-2512.	1.1	9
248	Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 3705-3733.	1.4	9
249	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , 1997, 26, 567-572.	3.6	9
250	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , 1979, 77, 629-33.	0.6	9
251	GB Virus-C Infection in Type 1 Autoimmune Hepatitis. <i>Mayo Clinic Proceedings</i> , 1998, 73, 412-418.	1.4	7
252	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 334-344.	1.0	7

#	ARTICLE	IF	CITATIONS
253	Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	7
254	GB virus-C infection in type 1 autoimmune hepatitis.. <i>Mayo Clinic Proceedings</i> , 1998, 73, 412-418.	1.4	7
255	Autoimmune Liver Disease. , 2004, , 121-125.		6
256	Progress in the diagnosis and treatment of autoimmune hepatitis. <i>Minerva Medica</i> , 2008, 99, 549-68.	0.3	6
257	Epigenetic Aspects and Prospects in Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
258	Management of Recalcitrant Autoimmune Hepatitis. <i>Current Hepatitis Reports</i> , 2013, 12, 66-77.	0.3	5
259	Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1286-1304.	1.9	5
260	Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4979-5005.	1.1	5
261	Autoimmune Hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, xi-xii.	1.0	4
262	Review article: targeting the B cell activation system in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 902-922.	1.9	4
263	Chronic Hepatitis. , 2006, , 729-747.		4
264	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2000, 16, 262-270.	1.0	3
265	Reply:. <i>Hepatology</i> , 2010, 52, 1857-1858.	3.6	3
266	Current management strategies for hepatocellular carcinoma. <i>Minerva Gastroenterologica E Dietologica</i> , 2013, 59, 143-59.	2.2	3
267	Examining micro-ribonucleic acids as diagnostic and therapeutic prospects in autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 591-607.	1.3	3
268	Special report: Autoimmune hepatitis. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 423-436.	0.3	2
269	Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion. <i>Hepatology</i> , 2010, 52, 1177-1184.	3.6	2
270	Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1449-1450.	1.9	2

#	ARTICLE	IF	CITATIONS
271	Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination. <i>Clinical Liver Disease</i> , 2020, 15, S72-S81.	1.0	2
272	Chapter 11 Immunopathogenesis of Autoimmune Liver Damage. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 8, 121-139.	0.1	1
273	Current Advances in the Treatment of Autoimmune Hepatitis. <i>Gastroenterology and Hepatology</i> , 2006, 2, 107-110.	0.2	1
274	Malignancy in chronic liver disease. <i>Gastroenterology</i> , 1977, 73, 192-3.	0.6	1
275	Correspondence. Liver Blood Flow Using Clearance Techniques. <i>Hepatology</i> , 1984, 4, 746-748.	3.6	0
276	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 268-275.	1.0	0
277	Arthur Joseph McCullough, Jr., 58th President, AASLD. <i>Hepatology</i> , 2008, 47, 775-776.	3.6	0
278	Letter: treatment of autoimmune acute liver failure - beyond consensus guidelines; author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1144-1144.	1.9	0
279	Letter: guidelines for the management of autoimmune hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 115-116.	1.9	0
280	Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 794-795.	1.9	0
281	Letter: high ferritin to haemoglobin ratio is related to early mortality in patients with alcoholic hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1457-1458.	1.9	0
282	Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis - offender or bystander? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 959-960.	1.9	0
283	Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1104-1105.	1.9	0
284	Editorial: the role of vitamin D in autoimmune hepatitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 343-344.	1.9	0
285	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases. , 2019, , 251-305.		0
286	Therapy of autoimmune diseases - state of the art. , 2000, , 311-324.		0
287	Overlap Syndromes of Primary Sclerosing Cholangitis. , 2017, , 41-57.		0
288	Autoimmune Liver Diseases: Autoimmune Hepatitis. , 2017, , 217-250.		0

#	ARTICLE	IF	CITATIONS
289	Autoimmune Liver Diseases: Overlap Syndromes. , 2017, , 307-328.		0
290	Diagnosis and management of chronic active hepatitis B. Comprehensive Therapy, 1988, 14, 46-53.	0.2	0